Cite
HARVARD Citation
Barlesi, F. et al. (n.d.). 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). European journal of cancer. pp. S635-. [Online].